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WE investigated the serum concentration of endosta-
tin in 84 patients with multiple myeloma (MM) and in
13 healthy controls. The level of measured anti-
angiogenic agent was correlated with the phase and
stage of the disease, and most importantly with
clinical and laboratory parameters depicting the
disease activity (haemoglobin, creatinine, albumins,
calcium, M-component, C-reactive protein, b2-micro-
globulin, lactate dehydrogenase, stage of bone dis-
ease) as well as serum levels of pro-angiogenic
cytokines such as vascular endothelial growth factor,
hepatocyte growth factor, fibroblast growth factor
and transforming growth factor-b. The median serum
level of endostatin in MM patients was 58 ng/ml and
was statistically significantly higher than in the
control group (median, 40 ng/ml; p/0.015). MM
patients in phase I (at diagnosis) had higher levels of
endostatin (median, 69 ng/ml) than those in phase II
(plateau phase after treatment) (median, 49 pg/ml;
p/0.044). We did not find any statistical correlation
between the level of endostatin and stage of MM
according to the Durie and Salmon system. The
serum concentration of endostatin in MM patients
with a normal level of albumins was significantly
higher than in others with hypoalbuminaemia (med-
ian, 62 ng/ml versus 39 ng/ml; p/0.033). Also,
patients with a normal value of lactate dehydrogen-
ase had a higher concentration of endostatin than
those with values  /425 U/l (median, 70 ng/ml versus
39 ng/ml; p/0.019). We did not show any statistical
correlation between the concentration of endostatin
and level of haemoglobin, creatinine, calcium, C-
reactive protein, b2-microglobulin and stage of bone
disease. We failed to find positive or negative correla-
tions between the level of endostatin and vascular
endothelial growth factor, hepatocyte growth factor,
fibroblast growth factor and transforming growth
factor-b. The concentration of endostatin did not
influence the probability of survival in MM patients
in our study.
In conclusion, our data indicate that endostatin has a
higher level in MM patients than in healthy controls.
Highest values were stated in active phases of the
disease (at presentation and in progression). Differ-
ent clinical and laboratory parameters generally do
not influence the concentration of endostatin (except
albumins and lactate dehydrogenase).
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Introduction
Angiogenesis is the key process in growth and
metastatic spread of neoplasms. In normal tissues
blood vessel growth is minimal and angiogenesis is
controlled by a balance of angiogenic stimulators and
inhibitors. This balance is perturbed in tumours to
favour angiogenesis either by overproduction of
angiogenesis inducers or by lack of inhibitors.
1 The
shift in balance between the production of anti-
angiogenic and pro-angiogenic factors is a process
called angiogenic switch and it marks the onset of
neovascularization, which is probably a key step
during tumour progression.
1,2 In earlier data it was
suggested that the generation of anti-angiogenic
compounds in the presence of primary tumour
suppresses the growth of distant metastases.
3
Recently, several naturally occurring inhibitors of
angiogenesis have been identified. The most potent
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229of them appears to be endostatin, the 20 kDa C-
terminal proteolytic fragment of the basement mem-
brane component collagen XVIII, isolated by O’Reilly
et al.
4 Endostatin is implicated in the regulation of
physiological and pathological angiogenesis. Its pre-
cise mechanism of action is still unclear. Endostatin
inhibits endothelial cell proliferation in vitro.
5,6
Different investigators have proposed the interfer-
ence of endostatin with such pro-angiogenic cyto-
kines as vascular endothelial growth factor (VEGF)
and fibroblast growth factor (FGF) (basic fibroblast
growth factor (bFGF)) pathways,
7 induction of en-
dothelial cell apoptosis,
8,9 inhibition of matrix metal-
loproteases,
10 and inhibition of endothelial cell
migration by modulating c-myc levels.
11
Endostatin possesses a prominent heparan sul-
phate binding domain, although it is not clear
whether this domain is required for anti-angiogenic
activity.
6,12 According to MacDonald et al., endostatin
binds tropomyosin in vitro and to tropomyosin-
associated microfilaments in a variety of endothelial
cell types.
13 The authors postulate that the interaction
of endostatin with tropomyosin results in the disrup-
tion of microfilament integrity, leading to the inhibi-
tion of cell motility, induction of apoptosis and
inhibition of tumour growth. Endostatin levels liber-
ated into culture media and administered exogen-
ously are decreased by hypoxia, the principal cause
of angiogenesis.
14
Recent successes in producing active human re-
combinant endostatin in yeast have allowed testing




18 Endostatin was shown to induce
tumour stabilization after chemotherapy or anti-CD20
immunotherapy in a mouse model of human high-
grade non-Hodgkin lymphoma. Tumour growth was
prevented in endostatin-treated mice as long as the
drug was administered. Enostatin administered on
days 25 /29 after tumour re-growth still induced
significant tumour regression, whereas chemother-
apy and anti-CD20 immunotherapy were not effec-
tive.
15 Fujii et al. demonstrated that endostatin
inhibits multiple myeloma (MM) growth and tumour
burden in the SCID-hu host system. It was reflected
by a reduction in serum levels of human monoclonal
immunoglobulins. Furthermore, mice bone density
was preserved, as demonstrated by X-ray evalua-
tion.
19 This fact may have therapeutical implica-
tions.
20
There is evidence that different diseases such as
connective tissue diseases, solid tumours, sarcomas
and even Down’s syndrome play a role in the
generation of endogenous anti-angiogenic proteins,
including endostatin.
21 26 Bertolini et al. first re-
ported plasma levels of endostatin in heamatologic
malignancies (non-Hodgkin lymphoma patients).
The authors did not notice any difference between
these levels in complete remission and progression of
the disease, as well as no correlation being found
between endostatin levels and event-free survival.
15
Kay et al. detected mRNA for endostatin in chronic
lymphocytic leukemia (CLL) patients.
27
MM cells are known to secrete pro-angiogenic
cytokines such as VEGF and FGF in vitro and in vivo.
VEGF expression is correlated with the severity of the
disease, and circulating VEGF is a prognostic factor
for the survival of MM patients.
28 Increased angio-
genesis in MM should result in high endostatin value.
The role of this most potent inhibitor of angiogenesis
is established on in vitro and animal models also in
MM,
16,19 but its clinical significance is not elucidated
at present.
Recent data demonstrate that MM cells can pro-
duce anti-angiogenic as well as pro-angiogenic
factors. In the present study we compare endostatin
serum level in different phases and stages of MM
using the enzyme-linked immunosorbent assay and
correlate its concentration with pro-angiogenic cyto-
kines such as VEGF, hepatocyte growth factor (HGF),
FGF and transforming growth factor-b (TGF-b).
Patients and methods
Patients
The study group comprised 84 patients with MM and
13 healthy controls comparable for median age and
gender distribution to the patient population. The
patients’ characteristics are presented in Table 1.
There were 43 women and 41 men with mean age
66.5 years (range, 32 /88 years) in the patient group.
The control group comprised seven women and six
men with mean age 65.9 years (range, 47 /80 years).
Table 1. Clinical and laboratory characteristics of MM
patients
Clinical/laboratory feature Number of patients (%)
Total 84 (100)
Sex (male/female) 45/43
Age (years) [median (range)] 68 (32 /88)
Phase I 57 (68)
Phase II 16 (19)
Phase III 11 (13)
Stage I 20 (24)
Stage II 16 (19)
Stage III 48 (57)
Bone disease 29/77 (38)
M-protein IgG 56 (67)
M-protein IgA 13 (15.5)
M-protein light chain 13 (15.5)
Non-secretory MM 2 (2)
Creatinine  /2 mg/dl 66 (79)
Haemoglobin B/10 g/dl 39 (46)
Albumin B/30 g/l 16 (19)
Calcium B/9 mg/dl 23 (27)
Calcium  /11 mg/dl 11 (13)
LDH  /425 U/l 26 (31)
LDH B/210 U/l 10 (12)
CRP  /5 mg/l 29 (34.5)
b2-microglobulin  /2.5 mg/l 59 (70)
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patients, IgA in 13 patients, light chain disease in four
patients and non-secretory myeloma in two cases.
Fifty-seven patients were studied at diagnosis (phase
I), 16 in the plateau (phase II) and 11 in the relapsed
disease (phase III). The plateau phase was stated
after 3 months of stable disease and achieving
complete (disappearance or decrease of M-compo-
nent  /90%) or partial (M-component decrease
 /50%) remission after chemotherapy. Twenty
patients were diagnosed in clinical stage I (IA, 20
patients; IB, 0 patients), 17 patients in clinical stage II
(IIA, 14 patients; IIB, three patients) and 47 patients
in clinical stage III (IIIA, 32 patients; IIIB, 15 patients)
according to the Durie and Salmon system.
29 Renal
failure (substage B) was diagnosed when the level of
creatinine was  /2 mg/ml, and was observed in 18
patients. Advanced bone disease was stated in 29 out
of 77 patients with at least multiple lytic lesions found
in X-ray examination. MM patients were treated with
different chemotherapy protocols adjusted to their
age and clinical status. One patient received high-
dose chemotherapy.
Laboratory examinations
All laboratory tests were performed on the day of
blood sampling for endostatin assay. Each patient’s
blood sample was examined for the following para-
meters: complete heamogram, serum protein electro-
phoretogram, immunoglobulins, urea nitrogen,
creatinine, calcium, lactate dehydrogenase (LDH),
C-reactive protein (CRP), b2-microglobulin, VEGF,
HGF, FGF and TGF-b. Serum b2-microglobulin levels
were measured by means of a radioimmunoassay kit.
Correction for renal function was not calculated.
Levels of immunoglobulins, albumin and CRP were
measured by nephelometry. Normal values of CRP
were considered as below 5.0 mg/l. Bone marrow
examination was performed in all cases, and X-ray
survey of flat bones in 77 patients.
Cytokine determination
Venous blood samples were collected on the day of
physical examination and laboratory tests. They were
collected in pyrogen-free tubes, allowed to clot for 1
ha t4 8C and centrifuged at 2000 x g for 10 min. The
obtained sera were aliquoted into separate vials and
stored at  /808C until assayed for endostatin and other
cytokines. Sera from each patient were randomly
coded and the measurement of cytokines was carried
out without the knowledge of the patient’s clinical
status and laboratory data. The obtained sera were
assayed for the concentration of endostatin (also for
VEGF, HGF, bFGF and TGF-b1). The commercially
available enzyme-linked immunosorbent assay kit
produced by Oncogene Research Products (Boston,
MA, USA) was used for endostatin detection, and
Quantikine, R & D Systems Inc. (Minneapolis, MN,
USA) products were used for the determination of the
remaining cytokines. All manufacturers’ instructions
were followed. The adsorbance was read at 492 nm.
The appropriate recombinant human cytokine was
used to generate the standard curve for each assay.
The concentration of cytokines in the samples was
determined by the interpolation from the standard
curve. This procedure has been described precisely
in our previous works.
30,31 The sensitivity limit for
endostatin was 1.95 ng/ml, for VEGF was 5.0 pg/ml,
for HGF was 40 pg/ml, for TGF-b1 was 7 pg/ml and
for bFGF was 3 pg/ml.
Statistical analysis
Statistical analysis was performed using the proce-
dures of Statistica for Windows package on the IBM-
compatible computer. The significance of cytokine
levels in different subsets of patients was assessed by
Mann /Whitney U, Kruskall /Wallis, Cochran /Cox
and Student tests where appropriate. p values
obtained from pair-wise comparisons were corrected
with the Bonferroni method. Zero values indicating
undetectable levels of cytokines were included in all
analyses. Correlations of analysed cytokines with
laboratory parameters and between cytokines were
calculated with Spearman‘s rank sum correlation
coefficient. All values quoted are two sided and
designated as statistically significant at the level
B/0.05. The overall survival was estimated using
the Kaplan /Meier method from the beginning of the
disease. All endpoints were updated on 31 August
2002. The survival period was analysed in two groups
of patients, below and above the median concentra-
tion value of endostatin, and compared using the F-
Cox test.
Results
The serum concentration values of endostatin in MM
patients and healthy controls are presented in Table 2.
Serum levels of endostatin were detectable in all
patients and in 12 out of 13 controls. The mean
concentration in the MM group was 72 ng/ml (range,
11 /402 ng/ml). The mean concentration of this
inhibitor in controls was 38 ng/ml (range, 0.0 /81
ng/ml; p /0.015). The mean level of endostatin was
highest in phases I and III of MM (mean, 77 ng/ml and
80 ng/ml, respectively). The concentration of this
agent in phase II was lower at 48 ng/ml, and there was
astatisticallysignificantdifferencebetweenthelevelof
endostatininphasesIandIIofthedisease(p /0.044).
The stage of MM according to Durie and Salmon
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influence the endostatin concentration (Table 2).
The mean concentration of endostatin in MM
patients with a normal level of albumins ( /30 g/l)
was 78 ng/ml, and was significantly higher than in
those with hypoalbuminaemia (46 ng/ml; p /0.033).
Similar results were obtained in correlation of endo-
statin with LDH. In patients with a normal concentra-
tion of LDH (B/210 and /425 U/l), the mean level of
this factor was significantly higher than in patients
with elevated LDH values (77 pg/ml versus 71 pg/ml,
p /0.019). The level of endostatin was lowest in light
chain disease patients (mean, 49 ng/ml) in compar-
ison with IgG MM (mean, 75 ng/ml) and IgA MM
(mean, 83 ng/ml). The light chain type did not
influence the level of this inhibitor. Endostatin
concentration did not correlate with other analysed
laboratory parameters such as haemoglobin, creati-
nine, total protein, calcium, CRP and b2-microglobu-
lin (Table 3).
In two patients with non-secretory MM, the endo-
statin concentrations were 35 and 68 ng/ml.
The endostatin serum level was correlated with
some pro-angiogenic cytokines such as VEGF, HGF,
FGF and TGF-b (Table 4). We did not find any
statistically significant correlation between endostatin
and these cytokines (Fig. 1).
The serum concentration of endostatin higher or
lower than its median value did not influence the
probability of survival of MM patients (Fig. 2).
Disscusion
The aim of our study was to evaluate the serum
concentration of an anti-angiogenic agent (endosta-
tin) in patients with MM, and to correlate it with
disease activity and advancement, the most important
clinical and laboratory parameters as well as known
pro-angiogenic cytokines such as VEGF, HGF, FGF
and TGF-b. The level of endostatin was detectable in
all 84 analysed MM patients and in 12 out of 13
healthy cotrols. Most authors report the detection of
endostatin in serum of the vast majority of patients
with solid tumours, soft tissue sarcomas, autoimmune
diseases and haematologic malignancies.
21 23,26,27,32
In our study, the concentration of endostatin in MM
patients was significantly higher than in healthy
individuals in comparable age. Higher values of this
agent were found in patients with MM before
treatment (phase 1 of the disease) than after therapy
(phase 2). We found no significant increase of
endostatin in advanced stages */ IIIA and IIIB of
the disease according to the Salmon and Durie
system */ as well as in advanced stages of bone
disease. The aggressiveness of MM in our data has no
association with the level of endostatin. Higher
values of that inhibitor were found in MM patients
with a normal level of albumins in comparison with
those with hypoalbuminaemia. Similarly, in cases of
MM with normal values of LDH, endostatin had
higher concentrations than in other patients with
decreased or elevated levels of LDH. We found no
correlation between the level of endostatin and the
Table 2. Serum levels of endostatin in MM patients at
different phases
MM patients Serum level of
endostatin
(ng/ml)
a. All (n /84) 729 /63 [58 (11 /402)]
b. Phase  / 1( n /57) 779 /65 [69 (11 /402)]
c. Phase  / 2( n /16) 489 /20 [49 (21 /87)]
d. Phase  / 3( n /11) 809 /85 [50 (27 /296)]
e. Control group (n /13, n1 /12) 389 /22 [40 (0 /80)]
Statistically significant comparison b versus c, p /0.04
b versus e, p /0.008
Data presented as mean9 /standard deviation [median (range)]. Phase
1, at the beginning; phase 2, plateau; phase 3, progression. n,
number of investigated individuals; n1, number of individuals with
detectable endostatin.
Table 3. Serum level of endostatin in MM patients correlated










 /10 g/dl 689 /55 Not significant
B/10 g/dl 779 /70
Creatinine
 /2 mg/dl 789 /91 Not significant
B/2 mg/dl 719 /54
Albumins
 /30 g/l 789 /67 0.033
B/30 g/l 469 /25
Calcium
 /11 mg/dl 739 /61 Not significant
9-11 mg/dl 669 /42
B/9 mg/dl 859 /97
M-component
IgG 759 /59 Not significant
IgA 839 /107
Light chain 499 /23
CRP
 /5 mg/l 689 /68 Not significant
B/5 mg/l 769 /58
b2-microglobulin
 /2.5 mg/l 749 /68 Not significant
B/2.5 mg/l 679 /49
LDH
a. /425 U/l 719 /87 a versus b, p /0.019
b. 210 /425 U/l 779 /51
c.B/210 U/l 529 /33
Stage of disease






0 /1 stage 679 /57 Not significant
2 /3 stage 829 /80
Data presented as mean9 /standard deviation.
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globin, creatinine, total protein value, calcium, CRP,
b2-microglobulin, immunoglobulin and light chain
isotype). Similar results were reported by Bertolini et
al. in non-Hodgkin lymphoma patients.
15 These
authors also stated lack of correlation between
endostatin levels with the grade of tumour malig-
nancy. They also found no difference in endostatin
concentration between patients in complete remis-
sion and progressive disease. Our data suggest that
the serum level of endostatin is lower in cases after
therapy and highest before treatment and in progres-
sion of MM. Feldman et al. measured the level of
endostatin in soft tissue sarcoma patients and stated
that the high pre-operative serum level predicted
poorer outcome.
21 Lai et al. showed that endostatin
has prognostic value in predicting complete remis-
sion and overall survival in patients with acute
myeloid leukaemia and myelodysplastic syn-
dromes.
32
In our previous study we showed positive correla-
tions between pro-angiogenic cytokines (VEGF and
TGF-b, bFGF and TGF-b, VEGF and bFGF) and our
data indicated a strong relationship between the
serum levels of these cytokines and clinical course,
as well as selected laboratory parameters of patients
with MM.
28 In this study we failed to prove the
correlation of the most potent anti-angiogenic factor,
endostatin, with these most clinically relevant pro-
angiogenic cytokines. Probably their interaction is
not direct, and further research is needed to elucidate
this problem.
We found no influence of endostatin level on the
probability of survival in our patients with MM.
Previously we stated that VEGF and FGF concentra-
tions have an effect on MM patients’ survival.
28 The
Table 4. Serum levels of VEGF, HGF, FGF and TGF-b in MM patients
Serum level/cytokine VEGF (pg/ml) HGF (pg/ml) FGF (pg/ml) TGF-b (ng/ml)
Mean9 /standard deviation 3249 /305 19409 /1400 89 /19 379 /15
Median 232 1270 2 36
Range 23 /1668 579 /4674 0 /108 3 /81
FIG. 1. Correlation between serum levels of endostatin and VEGF, HGF, TGF-b1 and FGF.
Endostatin in multiple myeloma
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the former was two times smaller, and probably these
proportions might influence the obtained results, so
further studies are needed in this field.
In conclusion, the present study is to our knowl-
edge the first report analysing the serum concentra-
tion and clinical significance of endostatin in a large
group of MM patients. Our data suggest that serum
endostatin levels are elevated in MM patients. The
elevated serum values of this agent are especially
relevant in patients before treatment and this is
caused by the high tumour mass at the beginning
of the disease. After treatment the level of this
inhibitor falls, and perhaps enables in that way the
intensification of angiogenesis during progression of
the disease. The plateau phase of MM seems then to
be the best time to apply therapy with endostatin.
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